Niagen® Plus Subcutaneous: Does it actually work?

Older man jogging on a park path

Kíral is one of the first companies to offer Niagen® Plus, a pharmaceutical-grade form of nicotinamide riboside (NR), as a subcutaneous (SubQ) injection. NAD+ is one of the most heavily marketed molecules in wellness, and the promise is usually the same: raise your NAD+ and your cells will run like new. The science is more complicated, and the details decide whether a product can do what it claims. This post walks through what the published research supports, including two manuscripts from our team (one published, one under review) and the first clinical trial of repeated at-home SubQ NR (currently in preprint).

The short version

  1. The molecule matters more than the route
    NAD+ is made inside your cells. NAD+ itself is unlikely to raise intracellular NAD+, whether it is taken orally, injected, or infused, because there is no validated transporter to carry it across the cell membrane, and it is broken down outside the cell first.¹,²
  2. NR is a different story
    Cells take up NR through dedicated transporters and convert it to NAD+ inside the cell.²,³
  3. Oral NR has the deepest evidence
    It reliably raises blood and tissue NAD+, is well tolerated, and has a variety of clinical effects.⁴⁻⁶
  4. Injectable NR is new
    Two small IV studies (one led by Dr. Pojednic) and one 90-day SubQ trial point to good tolerability. That is where the evidence stops for now.¹,²,⁷
  5. The SubQ data are early
    The SubQ trial was open-label, had no placebo group, and has not been peer reviewed. Whole-blood NAD+ did not rise over the 90 days.⁷

Why NAD+ by itself is a poor bet

NAD+ is a large, phosphorylated molecule with poor membrane permeability.³ Only 0.1 to 0.5 µM circulates in extracellular fluid under normal conditions, and NAD+ cannot be absorbed intact from the gut or taken up intact by cells.¹,² Enzymes outside the cell (CD73, CD38, and CD157) first break it down into NMN, NR, and nicotinamide, and cells take up those smaller pieces.¹ As Hawkins et al. put it, the scientific community “has not validated the presence of a cellular NAD+ transporter,” so NAD+ has to shed its phosphate groups and enter the cell as nicotinamide or NR.²

That requirement applies to oral, intramuscular, and IV NAD+ alike.² The obstacle is the molecule, not the route, and we see no reason a SubQ NAD+ injection would behave differently. This is why those straight NAD+ pens make us skeptical about any outcomes besides the placebo effect.

The obstacle is the molecule, not the route.

Extra extracellular NAD+ may also carry a cost. In preclinical work, NAD+ above its normal extracellular range acts as a danger signal with proinflammatory effects.¹,² In a randomized, placebo-controlled pilot, 500 mg of IV NAD+ did not significantly raise whole-blood NAD+ within 24 hours and was followed by increases in white blood cells and neutrophils, consistent with an inflammatory response.² NAD+ infusions are also slow. One controlled study needed a rate of 2 mg/min over 6 hours to give 750 mg without adverse events.²,⁸

So why do some people feel better after NAD+ infusions? Dr. Pojednic’s manuscript (currently under review) saw some of that. After four daily 500 mg infusions, the NAD+ group reported a significant improvement in sleep-related impairment and a larger drop in fatigue than the NR group, while the NR group had longer total sleep and a lower respiratory rate.³ But that study did not measure blood NAD+, so it cannot show that intracellular NAD+ rose. We point to other explanations, including adenosine released as extracellular NAD+ is broken down, regression to the mean, and the small size and baseline differences of the groups (5 to 8 people each).³ A subjective improvement is not evidence of intracellular NAD+ repletion.

What oral NR taught us

Oral NR is the best-studied form, so it is the reference point for everything else.

  1. It raises blood NAD+, and the rise depends on dose
    In an 8-week trial of overweight adults, 100, 300, and 1,000 mg a day raised whole-blood NAD+ by about 22%, 51%, and 142% within 2 weeks, and the rise held through day 56.⁴ In healthy middle-aged and older adults, chronic NR raised NAD+ in peripheral blood mononuclear cells by about 60% compared with placebo.⁵
  2. Raising NAD+ is the finding that replicates
    That consistency matters in human trials. Raising NAD+ is the one outcome that holds up across trials.⁶,⁹,¹⁰
  3. Clinical effects have been mixed
    A critical review of 25 published human NR trials found a multitude of clinically relevant effects, but outcomes have varied.⁶ NR did not improve insulin sensitivity in obese, insulin-resistant men at 2,000 mg a day for 12 weeks.¹¹ In healthy adults with obesity at 1,000 mg a day for 6 weeks, it increased fat-free mass and sleeping metabolic rate but did not change insulin sensitivity or mitochondrial function.¹² A 5-month twin study improved muscle mitochondrial number and satellite cell differentiation, but not adiposity or metabolic health.¹³
  4. It is well tolerated
    Trials up to 2,000 mg a day for 12 weeks reported no serious adverse events.⁹⁻¹¹ Unlike nicotinic acid, NR does not cause flushing. Minor effects include itching, sweating, bloating, and brief changes in stool.⁴,¹⁰ Niagen® (NR chloride) has GRAS status for use in foods and dietary supplements, which is a statement about oral use, not injection.²,⁴,¹⁰

Citation: Conze, D., Brenner, C. & Kruger, C.L. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep 9, 9772 (2019). doi:10.1038/s41598-019-46120-z

Injectable NR: what we know

Injection bypasses the gut, where a meaningful share of oral NR is converted to nicotinamide and nicotinic acid by BST1 and gut bacteria before it reaches the bloodstream.⁷ Injected NR may therefore give more direct and predictable exposure, but that is still a theory. No study has compared oral, IV, intramuscular, and SubQ NR head to head.⁷

  1. Hawkins et al., preprint
    Randomized, placebo-controlled pilot of a single 500 mg dose. Study 1 (n = 37) compared NAD+ IV, NR IV, saline, and oral NR. Study 2 (n = 16) compared NR IV and NAD+ IV head to head. No attributable adverse events through 14 days. NR infusions took about 75% less time than NAD+ infusions. Whole-blood NAD+ peaked 20.7% above baseline at 3 hours with NR IV, higher than NAD+ IV and oral NR (p < 0.01). White blood cells and neutrophils rose with NAD+ IV. Limits: pilot, single dose, preprint, and some dried blood spot samples were unusable.²
  2. Reyna et al. 2026
    Dr. Pojednic’s published retrospective review of commercial clients: NAD+ IV (n = 6) or NR IV (n = 8), 500 mg on 4 consecutive days, with 30-day follow-up. Infusions averaged 37 minutes with NR versus 97 with NAD+ (60% shorter). All 6 NAD+ clients reported moderate to severe symptoms, including GI symptoms, faster heart rate, and chest pressure. Some NR clients reported minor tongue, jaw, and arm tingling and mild cramping (one briefly paused an infusion for cramping). All of that resolved when infusions ended. No significant changes in ALT, AST, hsCRP, BUN/creatinine, or TSH. HbA1c fell in the NR group. Limits: retrospective, small, no placebo group, researchers employed by a commercial entity, and whole-blood NAD+ could not be analyzed because of insufficient sampling.¹
  3. Russ et al., preprint
    Open-label pilot (Part 2) of 39 adults with elevated fatigue who self-injected 50 mg (n = 18) or 100 mg (n = 21) SubQ three times weekly at home for about 90 days. All 39 completed all 6 clinic visits and no one withdrew. No serious adverse events. Three mild-to-moderate events, all in the 100 mg group (injection-site pain, hyperglycemia, hypertension). Vitals, chemistry, hematology, hsCRP, and homocysteine stayed stable. Whole-blood NAD+ stayed stable. Limits: no placebo group, open-label, small, sponsor-funded, and still a preprint.⁷

Inside the SubQ trial

To the authors’ knowledge, the SubQ trial is the first to evaluate repeated, self-administered NR injections over months.⁷ Participants were trained in clinic, then injected themselves into the abdomen and upper thigh with standard insulin syringes.⁷ Here is what it found.

  1. Safety and feasibility
    Adherence was self-reported and nobody dropped out. The participant with hyperglycemia likely had undiagnosed type 2 diabetes at baseline, so a causal link to NR cannot be established, and the authors recommend screening glucose in future studies.⁷
  2. Blood NAD+ did not climb
    Whole-blood NAD+ stayed stable at both doses over 90 days. Three consecutive daily injections in the earlier phase had raised it by day 3.⁷ The authors suggest that three doses a week may be too infrequent to sustain a rise, and that whole blood mostly reflects red cells, so it may miss changes in other tissues.⁷
  3. Exploratory signals
    Across all participants, the ratio of mitochondrial to glycolytic ATP production rose 41.3% by day 30 and stayed elevated at day 90. Fourteen of 16 urinary oxidative stress markers fell below baseline at one or more time points, and fatigue, sleep-related impairment, and global health scores improved by day 90. Self-reported facial skin improvement rose from 11.4% to 36.8%, although a small share of participants (3% to 8.3%) reported dryness, itching, or breakouts.⁷

How to read these results. Everyone knew they were getting NR, and there was no placebo group, so expectation could explain part of the change in how people felt. Enrollment required elevated fatigue, which makes regression to the mean likely. Sleep disturbance did not change, mitochondrial respiration was unchanged, and there was little sign of a dose response. The trial also ran over the winter holidays. The authors call their findings hypothesis-generating and say they need confirmation in placebo-controlled trials.⁷ Notably, the improvements appeared without a rise in blood NAD+. That may mean the effects happen in tissues that blood does not capture, or that they are not specific to NAD+ at all. This trial cannot tell the difference.

Where Kíral fits in

We offer Niagen® Plus SubQ at Kíral, but we are not claiming it is proven to raise your NAD+ or to change how you feel. NR has a sound mechanism and a deep oral evidence base. Injectable NR has early signs of good tolerability. The efficacy evidence for SubQ is one open-label trial.

The open questions are the ones that matter most: how SubQ compares with oral and IV dosing, how often to dose, what happens in tissues rather than blood, whether the benefits hold up against a placebo, and what happens over longer periods.⁷ SubQ NR is new enough to clinical research that every well-collected data point counts. Our team has published a study of IV NR and has another under review, and we want to bring the same rigor to SubQ. By carefully tracking outcomes and safety in the people we care for, we aim to add real-world data to the literature. That does not replace controlled trials, but it gives researchers and clinicians more to work with. We are hoping to use our data to help learn more about how and why SubQ Niagen Plus might be working in your body.

If you are considering SubQ NR, talk with your Kíral clinician about whether it fits your goals, what to realistically expect, and how we will monitor your response.

References

1. Reyna K, Heinzen G, Patel N, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. Published February 2, 2026. doi:10.3389/fragi.2026.1652582

2. Hawkins J, Idoine R, Kwon J, et al. Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen®+ IV and NAD+ IV in healthy adults. Preprint. medRxiv. Posted June 10, 2024. doi:10.1101/2024.06.06.24308565

3. Reyna K, Heinzen G, Patel N, et al. Sleep and quality-of-life after intravenous infusion of nicotinamide adenine dinucleotide (NAD+) or nicotinamide riboside (NR): self-reported measures and wearable-derived metrics. Manuscript under review. 2026.

4. Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9(1):9772. doi:10.1038/s41598-019-46120-z

5. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. doi:10.1038/s41467-018-03421-7

6. Damgaard MV, Treebak JT. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci Adv. 2023;9(29):eadi4862. doi:10.1126/sciadv.adi4862

7. Russ A, Nkrumah-Elie Y, Hailu F, et al. Part 2 of a 2-part open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 90 days of at-home subcutaneous injections. Preprint. medRxiv. Posted October 15, 2026. doi:10.64898/2026.10.13.26365470

8. Grant R, Berg J, Mestayer R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD. Front Aging Neurosci. 2019;11:257. doi:10.3389/fnagi.2019.00257

9. Yaku K, Nakagawa T. NAD+ precursors in human health and disease: current status and future prospects. Antioxid Redox Signal. 2023;39(16-18):1133-1149. doi:10.1089/ars.2023.0354

10. Connell NJ, Houtkooper RH, Schrauwen P. NAD+ metabolism as a target for metabolic health: have we found the silver bullet? Diabetologia. 2019;62(6):888-899. doi:10.1007/s00125-019-4831-3

11. Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353. doi:10.1093/ajcn/nqy132

12. Remie CME, Roumans KHM, Moonen MPB, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am J Clin Nutr. 2020;112(2):413-426. doi:10.1093/ajcn/nqaa072

13. Lapatto HAK, Kuusela M, Heikkinen A, et al. Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. Sci Adv. 2023;9(2):eadd5163. doi:10.1126/sciadv.add5163

This post is for educational purposes and isn’t medical advice. The evidence for injectable NR is early, and one of the key studies discussed here is a preprint that has not been peer reviewed.